[1] [1] RINELLA M E, LAZARUS J V, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Ann Hepatol, 2024, 29(1): 101133.

[2] [2] VACCA M, KAMZOLAS I, HARDER L M, et al. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. Nat Metab, 2024, 6(6): 1178-1196.

[3] [3] HAUSER A S, ATTWOOD M M, RASK-ANDERSEN M, et al. Trends in GPCR drug discovery: new agents, targets and indications[J]. Nat Rev Drug Discov, 2017, 16(12): 829-842.

[4] [4] MA B T, ZHU J J, TAN J, et al. Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway[J]. Am J Cancer Res, 2017, 7(3): 433-447.

[5] [5] WU M Y, LO T H, LI L P, et al. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (Adgrf1)[J]. eLife, 2023, 12: e85131.

[6] [6] BANERJEE S, PARK T, KIM Y S, et al. Exacerbating effects of single-dose acute ethanol exposure on neuroinflammation and amelioration by GPR110 (ADGRF1) activation[J]. J Neuroinflammation, 2023, 20(1): 187.

[7] [7] PARK T, CHEN H Z, KEVALA K, et al. N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling[J]. J Neuroinflammation, 2016, 13(1): 284.

[8] [8] TSUCHIDA T, LEE Y A, FUJIWARA N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J]. J Hepatol, 2018, 69(2): 385-395.

[9] [9] LIVAK K J, SCHMITTGEN T D. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method[J]. Methods, 2001, 25(4): 402-408.

[10] [10] ZHU X Y, QIAN Y, LI X W, et al. Structural basis of adhesion GPCR GPR110 activation by stalk peptide and G-proteins coupling[J]. Nat Commun, 2022, 13(1): 5513.

[11] [11] HUTCHINGS C J. A review of antibody-based therapeutics targeting G protein-coupled receptors: an update[J]. Expert Opin Biol Ther, 2020, 20(8): 925-935.

[12] [12] ROSENBAUM M I, CLEMMENSEN L S, BREDT D S, et al. Targeting receptor complexes: a new dimension in drug discovery[J]. Nat Rev Drug Discov, 2020, 19(12): 884-901.

[13] [13] KRISHNA KUMAR K, O'BRIEN E S, HABRIAN C H, et al. Negative allosteric modulation of the glucagon receptor by RAMP2[J]. Cell, 2023, 186(7): 1465-1477. e18.

[14] [14] LI Y, ZHOU Q T, DAI A T, et al. Structural analysis of the dual agonism at GLP-1R and GCGR[J]. Proc Natl Acad Sci USA, 2023, 120(33): e2303696120.

[15] [15] HUSTED A S, TRAUELSEN M, RUDENKO O, et al. GPCR-mediated signaling of metabolites[J]. Cell Metab, 2017, 25(4): 777-796.

[16] [16] IRACHETA-VELLVE A, CALENDA C D, PETRASEK J, et al. FXR and TGR5 agonists ameliorate liver injury, steatosis, and inflammation after binge or prolonged alcohol feeding in mice[J]. Hepatol Commun, 2018, 2(11): 1379-1391.

[17] [17] KIM H Y, SPECTOR A A. N-Docosahexaenoylethanolamine: a neurotrophic and neuroprotective metabolite of docosahexaenoic acid[J]. Mol Aspects Med, 2018, 64: 34-44.

[18] [18] HILGER D, MASUREEL M, KOBILKA B K. Structure and dynamics of GPCR signaling complexes[J]. Nat Struct Mol Biol, 2018, 25(1): 4-12.

[19] [19] CHEN K, ZHANG C H, LIN S L, et al. Tail engagement of arrestin at the glucagon receptor[J]. Nature, 2023, 620(7975): 904-910.

[20] [20] MARX V. Closing in on cancer heterogeneity with organoids[J]. Nat Methods, 2024, 21(4): 551-554.